AstraZeneca Pharma India Limited
NSE: ASTRAZEN | Information Technology
Market Fundamentals
Stock Intelligence & News
AstraZeneca, Daiichi Sankyo partner with Summit on cancer trial
AstraZeneca, Daiichi Sankyo partner with Summit on cancer trial
Read Full Analysis →Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Read Full Analysis →Medico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month
The Sensex fell 242 points to 72,529 as five BSE Healthcare Index stocks touched fresh 52-week lows. Medico Remedies, Pfizer, AstraZeneca Pharma India, Sanofi Consumer Healthcare India and Eris Lifesciences recorded their lowest prices in a year.
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal
Read Full Analysis →Why is AstraZeneca stock rallying today?
Why is AstraZeneca stock rallying today?
Read Full Analysis →AstraZeneca invests $2B in Summit Therapeutics for ADC trials
AstraZeneca invests $2B in Summit Therapeutics for ADC trials
Read Full Analysis →Summit stock surges on $2 billion AstraZeneca investment
AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.
Read Full Analysis →AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
Read Full Analysis →AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
Read Full Analysis →AstraZeneca shares oversold after trial flops and merger talk, says UBS
AstraZeneca shares oversold after trial flops and merger talk, says UBS
Read Full Analysis →Get instant alerts when ASTRAZEN breaks news
Join investors who track AstraZeneca Pharma India Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for ASTRAZEN?
ASTRAZEN is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for AstraZeneca Pharma India Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding ASTRAZEN to your custom watchlist.